Trials / Completed
CompletedNCT01656265
Study of ARQ 197 in Hepatocellular Carcinoma (HCC)
Phase I Study of ARQ 197 in Advanced Hepatocellular Carcinoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of ARQ 197 in hepatocellular carcinoma (HCC) patients treated with daily oral ARQ 197, to determine the recommended dose of ARQ 197 in advanced HCC patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARQ 197 | Daily repeating dose of oral ARQ 197, twice a day just after meals. Dose of ARQ 197 will be escalated according to 3+3 rule. |
Timeline
- Start date
- 2012-07-01
- Primary completion
- 2014-03-01
- Completion
- 2014-03-01
- First posted
- 2012-08-02
- Last updated
- 2017-03-03
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01656265. Inclusion in this directory is not an endorsement.